Clear superior benefit for leronlimab over the Placebo which happened to be SOC or any approved drug at hospitals disposable for covid-19. Leronlimab was superior in major ways albeit small data pool but in pandemic “if drug is considered SAFE and benefit outweighs risks qualifies for EUA” this was conveyed from former head of FDA Steven Hahn and Current Janet Woodcock. For full approval sure 140 more patients and hold CYDY to highest of standards but for EUA should have already been announced for critical population. The extra 140 will do nothing but point point to either current good benefit no risk with small sample of 62 or greater benefit with no risk. FDA is def not playing by same Set of guidelines with big pharm.